Lung Cancer Summit

7th October 2022

Lausanne University Hospital

Agora Pôle De Recherche Sur Le Cancer
View FlyerRegister Now

Solange Peters, MD-PhD

Solange Peters, MD-PhD, is Professor and chair of Medical Oncology as well as the Thoracic Malignancies programme in the department of oncology at Lausanne University Hospital, Switzerland. She has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably working as the current editor of the ESMO lung cancer clinical practice guidelines. She is the Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President ever, for a mandate in 2020-2021. She was also a member of the IASLC board of directors, and acts as vice president of the Swiss Group for Clinical Cancer Research lung group. She received both her doctorate in medicine and PhD from Lausanne University Hospital, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.

Alfredo Addeo, MD

Alfredo Addeo, MD, is a Consultant Medical Oncologist at the University Hospital of Geneva, Switzerland. He is the author of numerous national and international peer-reviewed publications in renowned scientific journals, including first- and last-author publications in the Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology. He has acted as a reviewer for several international scientific journals, including Journal of Thoracic Oncology and JAMA Oncology, and is an associate editor for Frontiers in Thoracic Oncology and guest editor for Precision Cancer Medicine. Dr. Addeo is an active ESMO member and a member of the EORTC lung group. He actively participates in ETOP (European Thoracic Oncology Platform) and SAKK (the Swiss Group for Clinical Cancer Research) and is a researcher and co-investigator of several national and international studies.

Following the great success of the virtual International Lung Cancer Summit (ILCS), we look forward to welcoming you to the 3rd edition of this interactive hybrid meeting. Similar to recent years, the ILCS will showcase latest discoveries and advances performed towards the treatment of lung cancer. The conference will leverage digital channels to provide with an exceptional outreach and opportunity for delegates from Medical Offices, Universities and Institutes to interact with world-class Medical Oncologists and Industry Professionals working in the field of lung cancer treatment and research.
The ILCS constitutes an ideal platform to share knowledge and seamless treatment procedures with our local and international speakers from the USA, Spain, Ireland, Israel, South Africa, Austria and Switzerland.

Join us and get your certificate of attendance during the conference. This meeting is accredited and CME-certified by the:

• Swiss Society of Medical Oncology: 5 credit points

• European Accreditation Council for Continuing Medical Education (EACCME): 4 credit points

5 SGMO CME Credits

Friday, 7 October 2022 – Live In Lausanne

Indicated Time Zone: Central European Summer Time (CEST)


Welcome by Chairs

Solange Peters & Alfredo Addeo


The power of pathology: biomarkers and targets we are testing today

Sabina Berezowska (Switzerland)


The many faces of EGFR mutations: each a different target

Alessandra Curioni (Switzerland)


ALK: old known with new expanded therapeutic options

Sze-Wai Chan (South Africa)


Open discussion & coffee break


Drugging the undruggables: the advent of KRAS and HER2 in NSCLC

Jair Bar (Israel)


METex14 and RET: important oncogenic factors for our treatment decision

Maximilian Hochmair (Austria)


Satellite Symposium 

Industry Symposium MSD:
“Surgery and immunooncology – advancing the outcomes in the peri-operative setting of early-stage NSCLC”

Speakers to be determined


Immunotherapies in good companionship: where do combination therapies make sense in advanced NSCLC – and where not?

Jarushka Naidoo (Ireland)



OS vs. DFS in early NSCLC

Disease free survival is an adequate endpoint for immuno- and targeted therapies in adjuvant NSCLC

Noemi Reguart (Spain)



OS vs. DFS in early NSCLC

OS is the only meaningful endpoint – also for adjuvant therapies

Wolf-Dieter Janthur (Switzerland)


Open discussion & coffee break


The path of immunotherapies to early NSCLC: my choice in stage I -III

Sandip Patel (USA)


Small Cell Lung Cancer: what are our options for SCLC in 1st and 2nd line today?

Stephen V. Liu (USA)


Do we follow our own commitments that we take away from congresses?

Panel Discussion With All

Join us in Lausanne:

Centre hospitalier universitaire vaudois – CHUV

Fondation ISREC, Bâtiment AGORA

Rue du Bugnon 25A

1005 Lausanne, Switzerland

or online right here!

The International Lung Cancer Summit 2022 is made possible with the kind support by our partners with no influence on the content:

MSD Logo
Janssen Logo
AstraZeneca Logo
Amgen Logo
Eli Lilly Logo
Takeda Logo
Roche Logo
Pfizer Logo
BMS Logo

for sponsoring opportunities, please contact us at








Follow Us For The Latest News on Twitter & LinkedIn

Join us at the #LungSummit22 LIVE or virtually ONLINE

📌Centre hospitalier universitaire vaudois – CHUV (@CHUVLausanne), Switzerland 🇨🇭

We look forward to welcoming you on 7th October at 10AM CEST 🙌

Register now ➡️

Image for the Tweet beginning: Join us at the #LungSummit22

Check out this new article by one of our #LungSummit panellists, on the effect of #chemotherapy on PD-L1 expression & TILs in #NSCLC 🫁

#OpenAccess article in @ModernPathology by Philipp Zens, Sabina Berezowska & colleagues➡️

Image for the Tweet beginning: Check out this new article

After decades of stagnation, we're seeing improved outcomes in #SCLC thanks to IO. Yet, the medical need for people with recurrent SCLC is incredibly large. See
@HosseinBorghaei from @FoxChaseCancer on what's new at #WCLC22 & relevant for our daily practice in this field.

Image for the Tweet beginning: After decades of stagnation, we're

We're extremely proud to see #LungSummit faculty member Dr. @StephenVLiu receive the Heine H. Hansen #SCLC lectureship award at @IASLC's #WCLC22.

Wonderful acknowledgement of Dr. Liu's work for the #lungcancer community! #LCSM

Image for the Tweet beginning: We're extremely proud to see

This year's #LungSummit is more global and community driven than ever 🌎

Join Sze-Wai Chan, alongside more incredible experts in the field to discuss the latest treatments and standard of care for #LungCancer 🫁

⏰ 7th Oct at 10AM CEST

Register now ➡️

Image for the Tweet beginning: This year's #LungSummit is more

The #ILCS ambition is to share knowledge on optimal treatments for people with #LungCancer from established experts around the globe and align on a common approach 🌎

Together, we can close the gap in medical education for this #WorldLungCancerDay 🫁


Image for the Tweet beginning: The #ILCS ambition is to

It's #WorldLungCancerDay & we're reminded of the continued medical gap in thoracic #oncology 🫁

Let's further the education of understanding #LungCancer together, & find more breakthroughs in early diagnosis & treatment for people around the world 🌎


Image for the Tweet beginning: It's #WorldLungCancerDay & we're reminded
Load More...